Document Detail


Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.
MedLine Citation:
PMID:  17953679     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To investigate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) in advanced diabetic foot ulcers (DFU) A double-blind trial was carried out to test two rhEGF dose levels in type 1 or 2 diabetes patients with Wagner's grade 3 or 4 ulcers, with high risk of amputation. Subjects were randomised to receive 75 (group I) or 25 mug (group II) rhEGF through intralesional injections, three times per week for 5-8 weeks together with standardised good wound care. Endpoints were granulation tissue formation, complete healing and need of amputation. Safety was assessed by clinical adverse events (AEs) and laboratory evaluations. Forty-one patients were included. After 5-8 weeks of treatment, 83% patients in the higher dose group and 61% in group II achieved useful granulation tissue covering more than 98% of the wound area. At long-term assessment, 13 (56.5%) patients healed in group I and 9 (50%) in group II. The mean time to complete healing in group I was 20.6 weeks (95% CI: 17.0-24.2) and 19.5 weeks (16.3-22.7) in group II. After 1-year follow-up, only one patient relapsed. Amputation was not necessary in 65% and 66.7% of groups I and II, respectively. The AEs rates were similar. The most frequent were sepsis (33%), burning sensation (29%), tremors, chills and local pain (25% each). rhEGF local injection enhances advanced DFU healing and reduces the risk of major amputation. No dose dependency was observed.
Authors:
José I Fernández-Montequín; Ena Infante-Cristiá; Carmen Valenzuela-Silva; Neobalis Franco-Pérez; William Savigne-Gutierrez; Heriberto Artaza-Sanz; Lourdes Morejón-Vega; Cecilio González-Benavides; Osvaldo Eliseo-Musenden; Elizeth García-Iglesias; Jorge Berlanga-Acosta; Ricardo Silva-Rodríguez; Blas Y Betancourt; Pedro A López-Saura;
Related Documents :
20462719 - Below the knee pta in critical limb ischemia results after 12 months: single center exp...
16520729 - Is it possible to predict outcome in mrsa positive patients undergoing arterial reconst...
10713199 - Does autonomic neuropathy influence spinal cord stimulation therapy success in diabetic...
19570689 - Subintimal angioplasty: meta-analytical evidence of clinical utility.
7850539 - Functional morbidity of hyperthermic isolated regional perfusion of the extremities.
3484519 - Spinal cord stimulation in peripheral arterial disease. a cooperative study.
22523379 - Mesh ablator vs. cryoballoon pulmonary vein ablation of symptomatic paroxysmal atrial f...
2239139 - Follow-up of antibiotically treated and untreated neuroborreliosis.
19744259 - Intralesional sodium stibogluconate alone or its combination with either intramuscular ...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2007-10-22
Journal Detail:
Title:  International wound journal     Volume:  4     ISSN:  1742-481X     ISO Abbreviation:  -     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-24     Completed Date:  2008-03-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101230907     Medline TA:  Int Wound J     Country:  England    
Other Details:
Languages:  eng     Pagination:  333-43     Citation Subset:  IM    
Affiliation:
Service of Diabetic Microangiopathy, National Institute for Angiology and Vascular Surgery, Havana, Cuba.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Amputation / statistics & numerical data
Analysis of Variance
Diabetes Mellitus, Type 1 / complications
Diabetes Mellitus, Type 2 / complications
Diabetic Foot / drug therapy*,  etiology,  surgery*
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Epidermal Growth Factor / administration & dosage*
Female
Follow-Up Studies
Granulation Tissue / drug effects
Humans
Injections, Intralesional
Male
Middle Aged
Probability
Risk Assessment
Severity of Illness Index
Statistics, Nonparametric
Treatment Outcome
Wound Healing / drug effects*
Chemical
Reg. No./Substance:
62229-50-9/Epidermal Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections.
Next Document:  Development of a 5'-nuclease PCR assay for the identification of Escherichia coli strains expressing...